Introduction {#Sec1}
============

Hepatitis B virus (HBV) infection remains a heavy health burden worldwide, especially in middle-low incomes countries. Chronic hepatitis B (CHB) affects an estimated 400 million people and increased risk of developing adverse outcomes, including cirrhosis, hepatic decompensation, and hepatocellular carcinoma \[[@CR1]\]. In the natural history of HBV infection, the role of hepatitis D virus (HDV) cannot be ignored \[[@CR2], [@CR3]\]. HDV is a defective RNA virus. HDV infection to hepatocyte is dependent on HBV infection \[[@CR3]\]. Previous studies reported that chronic infection with HDV exacerbates the poor prognosis of HBV infection \[[@CR4]\]. Patients with co-infection with HDV and HBV have an increased risk of cirrhosis and liver cancer \[[@CR4], [@CR5]\]. HBV chronic infection is also associated with some extrahepatic disease \[[@CR6], [@CR7]\]. Previous studies have confirmed that the association between HBV infection and non-Hodgkin's lymphoma (NHL) \[[@CR8]--[@CR11]\]. With regard to the NHL subtypes, a firm association was found with B-cell NHL, especially with diffuse large B-cell lymphoma (DLBCL), the most common subtype of B-cell NHL \[[@CR12], [@CR13]\]. In HBV prevalent countries, the patients with HBV was more likely to suffer from DLBCL \[[@CR7]\].

Rituximab is a chimeric anti-CD20 monoclonal antibody licensed for DLBCL treatment. Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the current standard chemotherapy for diffuse large B-cell lymphoma (DLBCL) \[[@CR14], [@CR15]\]. Recent evidences have shown that HBV reactivation was associated with the use of rituximab \[[@CR16], [@CR17]\]. Without prophylaxis, hepatitis B core antibody (HBcAb)-positive patients receiving rituximab therapy showed a high incidence of HBV reactivation \[[@CR18]--[@CR20]\]. Prophylaxis antiviral is recommended for these patients \[[@CR18], [@CR19]\]. However, the data on the difference of HBV related DLBCL and Non-HBV related DLBCL, and the incidence of HBV reactivation with its risk factors in DLBCL patients after R-CHOP anticaner therapy are still limited.

This retrospective study, therefore, was aim 1) to determine the difference of characteristics and prognosis between HBV related and Non-HBV related DLBCL, 2) to evaluate the occurrence of HBV reactivation in DLBCL patients, and 3) to identify risk factors for HBV reactivation in patients with DLBCL after R-CHOP anticancer therapy.

Subjects and methods {#Sec2}
====================

Subjects {#Sec3}
--------

All patients who were diagnosed with CD20+ DLBCL and treated with R-CHOP anticancer therapy were enrolled in this study from June. 2010 and June. 2015. The HBsAg status was determined before anticancer therapy. All patients underwent HBV serology tests, including those for HBsAb, hepatitis B e antigen (HBeAg), hepatitis B e antibody (HBeAb), and HBcAb. HBV serology, HBV DNA, and liver function (alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], and total bilirubin \[TB\] levels) were examed before each chemotherapy cycle and at least every 3 months during the follow-up period. Patients were excluded if there is evidences of hepatitis A virus (HAV), hepatitis C virus (HCV), hepatitis D virus, hepatitis E virus, or human immunodeficiency virus infection, coexistence of another type of lymphoma, associated chronic inflammation, and a previous malignancy.

HBV serological markers were determined using a commercially available radioimmunoassay (ARCHITECT i2000SR, Abbott Laboratories, 100 Abbott Park Road, Illinois, US). Serum HBV DNA levels were measured by real-time polymerase chain reaction with a linear range of 1000 IU/mL to 1 × 10^8^ IU/mL according to the manufacturer's instructions (Daan Gene Co, Ltd. of Sun Yat-sen University, Guangdong, China) \[[@CR21]\].

This study was approved by the Institutional Review Board of The Second Affiliated Hospital of Fujian Medical University. Informed consents for the collection of medical information were obtained from all patients at their first visit. All pathologic specimens were reviewed and reclassified according to World Health Organization (WHO) criteria.

Definitions in study {#Sec4}
--------------------

The international prognosis index (IPI) included five factors: age (≤60 years vs. \> 60 years), lactate dehydrogenase (LDH) value (≤245 U/mL vs. \> 245 U/mL), Eastern Cooperative Oncology Group (ECOG) performance status (PS) (0--1 vs. \> 1), Ann Arbor stage (I/II vs. III/IV), and the number of extranodal involvements (0--1 vs. \> 1). IPI scores were separated based on the number of factors present.

Statistical analysis {#Sec5}
--------------------

Overall survival (OS) was measured from the date of diagnosis to the date of death from any cause or to the date of the last follow-up visit. The associations of HBV reactivation and characteristics of patients were examined by univariate analysis, chi square or Fisher's exact test. Multivariate logistic regression analysis was performed to identify predictors of HBV reactivation. Survival curves were drawn by the Kaplan--Meier methodusing the log-rank test. Statistical significance was defined as *P* \<  0.05 (two-tailed). Statistical analysis was performed with SPSS version 13.0 software (Chicago, USA).

Results {#Sec6}
=======

Patients characteristics according to HBsAg status {#Sec7}
--------------------------------------------------

A total of 246 patients with DLBCL were enrolled in the study (Fig. [1](#Fig1){ref-type="fig"}). Among them, 80 patients were confirmed having HBsAg sero-positive and 166 patients were HBsAg sero-negative. The results showed that HBsAg sero-negative patients were significantly older than others (*P* \<  0.001). Patients with HBsAg sero-positive were more likely to have B symptoms (*p* = 0.002). Higher LDH level (*P* = 0.019) and late Ann Arbor stage (*P* = 0.010) were more often observed in patients with HBsAg sero-positive (Table [1](#Tab1){ref-type="table"}).Fig. 1Flow chart of the study. The flow chart of the study was shownTable 1Patients characteristics according to HBsAg statusVariableDiffuse large B-cell lymphoma*P* valueHBsAg-positiveHBsAg-negativeSample size80166Age, years\<  0.001  ≤ 6068 (85.0%)105 (63.3%)  \> 6012 (15.0%)61 (36.7%)Gender0.219 Male50 (62.5%)90 (54.2%) Female30 (37.5%)76 (45.8%)B symptom0.002 Positive46 (57.5%)60 (36.1%) Negative34 (42.5%)106 (63.9%)IPI score0.124 1--248 (60.0%)116 (69.9%) 3--532 (40.0%)50 (30.1%)LDH0.019 Normal35 (43.8%)99 (59.6%) Elevated45 (56.2%)67 (40.4%)Extranodal sites0.128  \< 244 (55.0%)108 (65.1%)  ≥ 236 (45.0%)58 (34.9%)Ann Arbor stage0.010 I-II19 (23.8%)67 (40.4%) III-IV61 (76.3%)99 (59.6%)Abbreviations: *HBsAg* hepatitis B surface antigen, *IPI* international prognosis index, *LDH* lactate dehydrogenase

Response to chemotherapy {#Sec8}
------------------------

To determine the difference of response rate to chemotherapy between two group, the responses rate was calculated and compared (Table [2](#Tab2){ref-type="table"}). The rate of complete response, partial response, stable disease and progress disease of DLBCL in HBsAg sero-negative group were 63.9, 16.9, 1.1 and 18.1%, respective, which was significantly higher than that in HBsAg sero-positive group with the rate of complete response, partial response, stable disease and progress disease being 36.2, 18.8, 1.2 and 43.8%.Table 2Proportion of patients with Response to chemotherapyResponse to chemotherapyDiffuse large B-cell lymphoma*P* valueHBsAg-positiveHBsAg-negativeSample size80166Response\<  0.001 Complete response29 (36.2%)106 (63.9%) Partial response15 (18.8%)28 (16.9%) Stable disease1 (1.2%)2 (1.1%) Progress disease35 (43.8%)30 (18.1%)

Kaplan-Meier analysis showed the overall survival between HBsAg sero-positive patients and HBsAg sero-negative was significantly different (*P* = 0.003). As shown in Fig. [2](#Fig2){ref-type="fig"}, patients of DLBCL with HBsAg sero-negative have better prognosis.Fig. 2Kaplan-Meier analysis of DLBCL with or without HBV infection. Results showed the overall survival between HBsAg sero-positive patients and HBsAg sero-negative was significantly different (*P* = 0.003)

Patients characteristics according to HBV reactivation {#Sec9}
------------------------------------------------------

A total of 17 patients showed HBV reactivation among 166 patients with HBsAg sero-negative after R-CHOP treatment. The characteristics of patients were shown in Table [3](#Tab3){ref-type="table"}. All patients experienced HBV reactivation were HBcAb positive before treatment (*P* \<  0.001). The HBsAb positive rate were significantly lower in patients with HBV reactivation than the others (*P* = 0.021). The serum HBV DNA level in patients during reactivation was 4.38 ± 2.25 log~10~IU/mL.Table 3Patients characteristics according to HBV reactivationVariableHBsAg (−) Diffuse large B-cell lymphoma*P* valueHBV reactivationNon-HBV reactivationSample size17149Age, years0.869  ≤ 6011 (64.7%)94 (63.1%)  \> 606 (35.3%)55 (36.9%)Gender0.911 Male9 (52.9%)81 (54.3%) Female8 (47.1%)68 (45.7%)B symptom0.542 Positive5 (29.4%)55 (36.9%) Negative12 (70.6%)94 (63.1%)IPI score0.108 1--29 (52.9%)107 (71.8%) 3--58 (47.1%)42 (28.2%)LDH0.264 Normal8 (47.1%)91 (61.1%) Elevated9 (52.9%)58 (38.9%)Extranodal sites0.128  \< 211 (64.7%)97 (65.1%)  ≥ 26 (35.3%)52 (34.9%)Ann Arbor stage0.135 I-II4 (23.5%)63 (42.3%) III-IV13 (76.5%)86 (57.7%)HBcAb status\<  0.001 Positive17 (100%)46 (30.9%) Negative0 (0.0%)103 (69.1%)HBsAb status0.021 Positive8 (47.1%)110 (73.8%) Negative9 (52.9%)39 (26.2%)Abbreviations: *HBsAb* hepatitis B surface antibody, *IPI* international prognosis index, *LDH* lactate dehydrogenase

To further confirm the relationship between HBsAb and HBV reactivation. The proportion of HBV reactivation according HBsAb level were calculated among the 166 patients with HBsAg sero-negative before treatment. A significantly different were observed with 18.75% (9/48) patients with HBV reactivation in HBsAb negative group, 8.25% (8/97) patients in HBsAb level 10--100 U/mL group, and 0% patients in HBsAb level higher than 100 U/mL group. As shown in Fig. [3](#Fig3){ref-type="fig"}.Fig. 3The proportion of HBV reactivation according HBsAb level. A significantly different were observed with 18.75% (9/48) patients with HBV reactivation in HBsAb negative group, 8.25% (8/97) patients in HBsAb level 10--100 U/mL group, and 0% patients in HBsAb level higher than 100 U/mL group

Univariate and multivariate analyses of risk factors associated with HBV reactivation {#Sec10}
-------------------------------------------------------------------------------------

A univariate and multivariate analyses were conducted to analysis the risk factor associated with HBV reactivation. The univariate analyses indicated serum HBsAb and HBcAb were risk factors associated with HBV reactivation after R-CHOP chemotherapy. Similarly, multivariate analyses show that low HBsAb level (OR = 0.917, *P* = 0.044) and positive HBcAb level (OR = 2.201, *P* \<  0.001) were independent risk factors associated with HBV reactivation in DLBCL patients receiving R-CHOP chemotherapy (Table [4](#Tab4){ref-type="table"}).Table 4Univariate and multivariate analyses for HBV reactivationVariablesUnivariate analysisMultivariate analysisHR95% CIPHR95% CI*P*Age, years0.8710.749--1.1130.173Sex1.0130.784--1.3080.921B symptom1.0770.857--1.3530.526IPI score1.0730.811--1.4190.621LDH0.9780.802--1.1920.822Extranodal sites1.0890.884--1.3410.424Ann Arbor stage0.9920.763--1.2890.951HBsAb0.8180.570--0.8970.0370.9170.705--0.9940.044HBcAb2.2651.085--3.474\<  0.0012.2011.028--2.703\<  0.001Abbreviations: *HBsAb* hepatitis B surface antibody, *IPI* international prognosis index, *LDH* lactate dehydrogenase. *HBcAb* hepatitis B core antibody

Discussion {#Sec11}
==========

This study demonstrated that the characteristics and prognosis were significantly different between HBV related DLBCL than non-HBV related DLBCL. For those DLBCL patients who were have both HBsAg sero-negative, they had a significantly higher risk of HBV reactivation compared with HBsAg-negative/HBcAb-negative patients after rituximab containing chemotherapy. Baseline HBcAb positivity and HBsAb negativity were independent risk factors for HBV reactivation in patients with DLBCL.

Chronic HBV infection was considered to be associated with lymphomagenesis, especially for DLBCL \[[@CR22]\]. Also, several studies have demonstrated that the incidence of HBV infection was higher in patients with B-cell lymphoma than in the general population \[[@CR23], [@CR24]\]. Furthermore, our study demonstrated that CD20+ DLBCL patients with resolved HBV infection were more likely to experience HBV reactivation, compared with HBsAg-negative/HBcAb-negative patients using rituximab containing chemotherapy.

In this study, it stands to reason that DLBCL patients with HBsAg-negative/HBcAb-positive should monitor HBV serology, HBV DNA closely before each chemotherapy cycle. Furthermore, prophylactic antiviral treatments were thus recommended for HBsAg-negative/HBcAb-positive patients. Consistently, study recommend prophylaxis with antiviral drugs in all HBsAg-negative/HBcAb-positive patients who receive rituximab-containing regimens for hematologic malignancies because of a high risk of HBV reactivation \[[@CR25]\]. Lamivudine is widely used for prophylaxis, while its efficacy is hampered by the development of viral mutations result in drug resistance \[[@CR26]--[@CR28]\]. Currently, the FDA approves antiviral drugs for inhibiting HBV replication, in addition to LAM, as well as telbivudine, adefovir, entecavir and tenofovir. Among them, LAM, telbivudine and adefovir are low-resistance barriers antiviral agents, while entecavir and tenofovir are antiviral drugs with potent anti-HBV effect and high-resistance barriers, so they are recommended as first-line drugs by various guidelines \[[@CR29]--[@CR31]\]. Maybe others antiviral agents such as entecavir and tenofovir would be more effective and associated with minimal resistance \[[@CR32], [@CR33]\], but it still need further study to confirm.

Our study had several key points. We compared the characteristics and prognosis between HBV related DLBCL than non-HBV related DLBCL. We also compared the incidence of HBV reactivation between HBcAb-positive and HBcAb-negative patients and identified risk factors for the occurrence of HBV reactivation. China is a high endemic HBV burden area \[[@CR34]--[@CR36]\], and this is the first study to confirm these findings However, this study was limited by its retrospective nature. Another limitation was that all the patients were come from a single institute. Prospective studies including more patients from more centres are required to confirm our findings and to determine the most effective monitoring and therapeutic strategies.

In conclusion, this study demonstrated that the characteristics and prognosis were different between HBV related DLBCL than non-HBV related DLBCL patients. DLBCL patients with resolved hepatitis B were at a higher risk of developing HBV reactivation after rituximab containing chemotherapy compared with HBsAg-negative/HBcAb negative patients. Close monitoring of HBV DNA levels and liver function and prompt antiviral therapy are required in these patients. More large-scale studies are required to identify host and viral factor that can help to predict the occurrence of HBV reactivation and thus allow the design of individualized strategies for preventing HBV-related hepatitis.
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